Orme, Jonathan P.

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

Floc'h, N., Martin, M. J., Riess, J. W., Orme, J. P., Staniszewska, A. D., Ménard, L., Cuomo, M. E., O'Neill, D. J., Ward, R. A., Finlay, M. R. V., et al. (2018) · Molecular Cancer Therapeutics

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 115

An automated cell line authentication method for AstraZeneca global cell bank using deep neural networks on brightfield images

Tong, L., Corrigan, A., Kumar, N. R., Hallbrook, K., Orme, J., Wang, Y., & Zhou, H. (2022) · Scientific Reports

Cell Image Analysis TechniquesDigital Imaging for Blood Diseases

Cited by 6